Amarantus Bioscience Holdings Inc (AMBS)

[Solantey]

After the company failed to release the MANF comparative study data last week I became a bit suspicious that the data may not be as good as expected.

There was no reason for the company to delay the release of positive data for almost three weeks and stop the upward momentum in the share price.

Obviously others started to believe the same thing as today's sell off demonstrated.

It's not nice to fool the shareholders.

p.s. The "kiting" of press releases made this seem more and more like a "pump and dump".